Accelerated conditions for stability assessment of bulk and formulated monohydrate

Pharmaceutical Development and Technology

Volumn 2, Issue 4, 1997, Pages 303-312

  Olsen, Bernard A ^a   Perry, Fred M ^a   Snorek, Sharon V ^a   Lewellen, Peggy L ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Accelerated stability; Amorphous; Cefaclor monohydrate; Solid state degradation

Indexed keywords

CEFACLOR;

ARTICLE; DRUG DEGRADATION; DRUG FORMULATION; DRUG MANUFACTURE; DRUG STABILITY; PRIORITY JOURNAL; TEMPERATURE SENSITIVITY;

EID: 0031399269     PISSN: 10837450     EISSN: None     Source Type: Journal    
DOI: 10.3109/10837459709022629     Document Type: Article

References (16)

1. U.S. Food and Drug Administration, Guideline for Submitting Documentation for the Stability of Human Drugs and Biologies, February 1987.
2. International Conference on Harmonisation, Stability testing of new drug substances and products, Federal Register, 59, 48754-48759 (1994).
3. M. J. Pikal and K. M. Dellerman, Stability testing of pharmaceuticals by high-sensitivity isothermal calorimetry at 25°C: cephalosporins in the solid and aqueous solution states, Int. J. Pharm., 50, 233-252 (1989).
4. M. J. Pikal, A. L. Lukes, J. E. Lang, and K. Gaines, Quantitative crystallinity determinations for β-lactam antibiotics by solution calorimetry: correlations with stability, J. Pharm. Sci., 67, 767-773 (1978).
5. United States Pharmacopeia 23, Third Supplement, Rockville, MD, November 15, 1995, p. 2905.
6. European Pharmacopeia, 19th Fasicule, Maisonneuve, Saint-Ruffine, France, January 1996.
7. L. J. Lorenz, F. N. Bashore, and B. A. Olsen, Determination of process-related impurities and degradation products in cefaclor by high-performance liquid chromatography, J. Chrom. Sci., 30, 211-216 (1992).
8. B. A. Olsen, S. W. Baertschi, and R. M. Riggin, Multidimensional evaluation of impurity profiles for generic cephalexin and cefaclor antibiotics. J. Chromatogr., 648, 165-173 (1993).
9. United States Pharmacopeia 23, Rockville, MD, 1995, p. 284.
10. S. R. Byrn, Solid-State Chemistry of Drugs, Academic Press, New York, 1982, pp. 60-65.
11. R. R. Pfeiffer, K. S. Yang, and M. A. Tucker. Crystal pseudopolymorphism of cephaloglycin and cephalexin, J. Pharm. Sci., 59(12), 1809-1814 (1970).
12. J. T. Carstensen, M. Franchini, M. Pudapeddi, and T. Morris, Reaction orders of decompositions of anhydrous amorphates, Drug Dev. Ind. Pharm., 19(15), 1811-1820 (1993).
13. C. Ahlneck and G. Zografi, The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state, Int. J. Pharm., 62, 87-95 (1990).
14. J. T. Carstensen, Accelerated stability testing of stoichiometric hydrates, Pharm. Tech., 10(9), 98-100 (1986).
15. M. Otsuka and N. Kaneniwa, Effect of grinding on the degree of crystallinity of cephalexin powder, Chem. Pharm. Bull., 31(12), 4489-4495 (1983).
16. J. T. Carstensen, A. Gerhardt, T. Morris, and F. Nikfar, Effect of moisture on solid dosage forms. Can the Arrhenius equation be used as a predictor., Drug Dev. Ind. Pharm., 16(15), 2267-2281 (1990).